Can Mavacamten Help You Exercise More?
Part of Heart & circulation clinical trials.
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hypertrophic obstructive cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow).
- You've been taking mavacamten for at least 12 weeks at the same dose.
- Your heart's pressure gradient is 50 mmHg or less at rest and during stress.
- Your heart's pumping strength (ejection fraction) is 50% or more.
- Your heart failure symptoms are mild (class I or II on the NYHA scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study tests whether adding the drug mavacamten to a heart procedure (radiofrequency ablation) helps people with a thickened heart muscle that blocks blood flow. It may reduce symptoms like chest pain or shortness of breath.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Hear when a new Cardiomyopathy, Hypertrophic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.